Cardiff Oncology shares plunge after Q2 earnings miss
On Tuesday, Jefferies analysts began coverage on Elis SA stock, assigning a Buy rating. The analysts set a price target of €30.00, highlighting their optimistic outlook for the company.
The analysts pointed to Elis SA’s resilient profile and promising medium-term growth prospects. They noted an expected adjusted EPS compound annual growth rate (CAGR) of approximately 7% from 2024 to 2027.
Jefferies sees potential upside risks for the company due to a shift in its capital allocation policy, which could enhance its growth trajectory. This policy change is expected to strengthen the company’s operating and balance sheet profile.
The analysts believe that consistent performance in executing its growth strategy could lead to an expansion in valuation multiples for Elis SA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.